Overview

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Status:
RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Phase:
PHASE2
Details
Lead Sponsor:
Hoffmann-La Roche